Esoterix, INC
Esoterix, INC was paid $4.00M by Medicaid between Jan 2018 and Dec 2024, across 89 billing codes. Its largest line is 81220, CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants — 29% of everything it billed.
CALABASAS HILLS, CA 91301
Next to other Clinical Medical Laboratory providers in California
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,038 | $611K | |
| 2019 | 16,192 | $600K | |
| 2020 | 17,781 | $397K | |
| 2021 | 31,625 | $358K | |
| 2022 | 41,014 | $487K | |
| 2023 | 63,298 | $740K | |
| 2024incomplete | 64,056 | $806K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 29% | 5,484 | 5,150 | $1.15M |
| 86235 | 8.1% | 7,096 | 6,167 | $323K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 7.1% | 21,255 | 20,079 | $284K |
| 84403 | 6.5% | 14,509 | 13,256 | $259K | |
| 84443 | Thyroid stimulating hormone (TSH) | 3.5% | 13,508 | 12,663 | $139K |
| 86147 | 3.4% | 3,434 | 3,049 | $134K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.1% | 21,073 | 20,112 | $123K |
| 81490 | 2.9% | 2,030 | 1,900 | $118K | |
| 82397 | 2.2% | 13,181 | 11,879 | $88K | |
| 84439 | 1.9% | 15,991 | 15,093 | $77K | |
| 82533 | 1.8% | 5,996 | 4,603 | $72K | |
| 82670 | 1.7% | 3,651 | 3,433 | $67K |
77 more codes
| 86160 | 1.6% | 4,629 | $64K | |
| 86341 | 1.5% | 3,664 | $60K | |
| 84481 | 1.2% | 4,392 | $49K | |
| 82627 | 1.1% | 3,442 | $46K | |
| 86337 | 1.1% | 3,602 | $43K | |
| 86376 | 1.1% | 5,241 | $43K | |
| 83002 | <1% | 3,813 | $39K | |
| 83001 | <1% | 3,739 | $38K | |
| 86038 | <1% | 5,569 | $38K | |
| 83498 | <1% | 2,964 | $36K | |
| 86225 | <1% | 4,554 | $35K | |
| 86200 | <1% | 5,257 | $35K | |
| 82166 | <1% | 2,434 | $33K | |
| 83520 | <1% | 4,159 | $32K | |
| 84305 | <1% | 2,736 | $31K | |
| 84146 | <1% | 2,339 | $30K | |
| 84270 | <1% | 2,156 | $29K | |
| 83516 | <1% | 3,425 | $29K | |
| 82542 | <1% | 2,161 | $25K | |
| 84402 | <1% | 1,703 | $23K | |
| 83525 | <1% | 4,260 | $23K | |
| 80230 | <1% | 1,373 | $22K | |
| 80299 | <1% | 2,503 | $21K | |
| 84410 | <1% | 733 | $21K | |
| 86800 | <1% | 2,216 | $21K | |
| 84432 | <1% | 2,241 | $19K | |
| 86256 | <1% | 2,528 | $19K | |
| 84482 | <1% | 1,497 | $18K | |
| 82652 | <1% | 884 | $16K | |
| 84466 | <1% | 1,882 | $15K | |
| 83527 | <1% | 2,416 | $15K | |
| 80145 | <1% | 983 | $14K | |
| 86431 | <1% | 5,429 | $14K | |
| 84378 | <1% | 2,022 | $13K | |
| 82642 | <1% | 996 | $13K | |
| 83519 | <1% | 1,335 | $12K | |
| 84150 | <1% | 292 | $11K | |
| 83970 | <1% | 454 | $11K | |
| 84140 | <1% | 964 | $10K | |
| 82681 | <1% | 647 | $10K | |
| 82157 | <1% | 1,076 | $9K | |
| 84144 | <1% | 792 | $8K | |
| 86381 | <1% | 578 | $7K | |
| 82657 | <1% | 460 | $5K | |
| 84143 | <1% | 638 | $5K | |
| 82088 | <1% | 211 | $5K | |
| 86036 | <1% | 853 | $4K | |
| 82784 | <1% | 593 | $4K | |
| 84433 | <1% | 311 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 69 | $3K |
| 86015 | <1% | 471 | $3K | |
| 83540 | <1% | 756 | $3K | |
| 82523 | <1% | 426 | $3K | |
| 86366 | <1% | 123 | $2K | |
| 82010 | <1% | 519 | $2K | |
| 84480 | <1% | 207 | $2K | |
| 83003 | <1% | 56 | $2K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 459 | $2K |
| 84244 | <1% | 188 | $2K | |
| 80220 | <1% | 699 | $2K | |
| 84702 | <1% | 205 | $2K | |
| 84153 | <1% | 167 | $2K | |
| 82728 | <1% | 191 | $1K | |
| 84436 | <1% | 290 | $1K | |
| 80197 | <1% | 102 | $1K | |
| 84681 | <1% | 105 | $1K | |
| 80280 | <1% | 71 | $940.56 | |
| 82626 | <1% | 109 | $824.19 | |
| 86146 | <1% | 14 | $668.55 | |
| 80061 | Lipid panel | <1% | 122 | $630.41 |
| 80053 | Comprehensive metabolic panel | <1% | 73 | $326.91 |
| 82570 | <1% | 73 | $297.40 | |
| 86255 | <1% | 32 | $239.60 | |
| 82679 | <1% | 12 | $165.83 | |
| 82634 | <1% | 19 | $110.08 | |
| 82043 | <1% | 12 | $66.00 | |
| 84999 | <1% | 80 | $56.49 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.